Overexpression of IL-17RC associated with ocular sarcoidosis by Wenting Wu et al.
Wu et al. Journal of Translational Medicine 2014, 12:152
http://www.translational-medicine.com/content/12/1/152RESEARCH Open AccessOverexpression of IL-17RC associated with
ocular sarcoidosis
Wenting Wu1,2,3, Ming Jin3, Yujuan Wang1,4, Baoying Liu1, Defen Shen1, Ping Chen1, Susan Hannes1, Zhiyu Li1,
Sima Hirani1, Shayma Jawad1, UNITE Human Ocular Inflammation Consortium, H Nida Sen1, Chi-Chao Chan1,
Robert B Nussenblatt1* and Lai Wei1,4*Abstract
Background: Sarcoidosis is a chronic inflammatory disease with a systemic granulomatous disorder affecting multiple
organs including the eye. Both CD4+ T cell and macrophage have been linked to the pathogenesis of the disease.
Methods: The expression of IL-17RC was measured using FACS,immunohistochemistry and real-time PCR. Serum level
of IL-17 was detected using ELISA.
Results: An elevated expression of IL-17RC on CD8+ T cells in peripheral blood was found in patients with ocular
sarcoidosis as compared to healthy controls. Interestingly, we found a significant increase in the serum level of IL-17 in
patients with ocular sarcoidosis as compared to healthy controls, which may be responsible for the induction of IL-17RC
on CD8+ cells. In addition, IL-17RC appeared only in the retinal tissue of the patient with clinically active sarcoidosis.
Conclusions: Our results suggested a potential involvement of IL-17RC+CD8+ T cells in pathogenesis of ocular
sarcoidosis.
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Sarcoidosis is a systemic granulomatous disorder affect-
ing multiple organs. Chronic inflammation occurs pre-
dominantly in the lung. In addition, lymph node,
gastrointestinal tract, skin, nervous system, liver, spleen,
heart, kidney, and muscle can also be affected. Ocular
involvement is found in 25-50% patients with sarcoidosis
and can be the first clinical manifestation of the disease
according to several American and European studies
[1,2]. However, ocular involvement may be found in up
to 89% of Japanese patients with systemic sarcoidosis,
suggesting a potential racial difference of its clinical
presentation. Ocular sarcoidosis can occur in the ab-
sence of other systemic manifestations. Although the
diagnosis of sarcoidosis can be confirmed by biopsy of
the skin, conjunctiva, peripheral lymph nodes, or lung,
the etiology of sarcoid granulomas is unknown [1].* Correspondence: drbob@nei.nih.gov; weil9@mail.sysu.edu.cn
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unless otherwise stated.Recent studies suggest sarcoidosis susceptibility is
dependent on both genetic and environmental risk fac-
tors [3]. All races can suffer from sarcoidosis. Aggrega-
tion among certain racial/ethnic groups [4], as well as
increased concordance among monozygotic twins [5]
both strongly support the probability of a genetic sus-
ceptibility to sarcoidosis. Recent case–control genetic
studies and genome-wide association studies (GWAS)
identified multiple single nucleotide polymorphisms
(SNPs) that may be associated with sarcoidosis. These
include polymorphisms within coding regions of HLA-
DRB1 and HLA-DQB1, CARD15 (caspase recruitment
domain family member 15)/NOD2 (nucleotide-binding
oligomerization domain containing 2), BTNL2 (butyro-
philin-like protein 2), ANXA11 (annexin A11), RAB23
(RAB23, member RAS oncogene family), and CFH
(complement factor H) [6-14]. Moreover, exposure to
musty odors and insecticides [15], as well as infectious
agents including Propionibacterium acnes and Mycobac-
terium tuberculosis [16-18] found within sarcoid granu-
lomas have been proposed as important environmental
and occupational risk factors for sarcoidosis. Therefore,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,






Gender (M/F) 5/8 13/5
Ave. Age 44 43
Race (AA/C/H*) 11/2/1 18/0
Ocular sarcoid 13 (100%) -
Neuro/Pulmonary/Joint Sarcoid 1(8%)/2 (15%)/1(8%) -
Active disease 3 (23%) -
Biopsy proven 10 (77%) -
Medication
Corticosteroid** 10 (77%) -
Immunosuppressive agent*** 7 (54%) -
Opioid 4 (31%) -
Hypertension drug 3 (23%) -
Heart disease drug 3 (23%) -
Diabetic Medication 4 (31%) -
Calcium 4 (31%) -
*AA African American; C Caucasian; H Haitian.
**Include Prednisone, Prednisolone Acetate, Difluprednate, Desonide, Retisert.
***Include mycophenolate Mofetil, Cyclosporine, Methotrexate.
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triggered by environmental and infectious agents in gen-
etically susceptible individuals. However, it is unclear
whether the different clinical manifestations presented
in sarcoidosis patients are due to the unique etiology.
For example, no clear genetic and environmental risk
has been identified for ocular sarcoidosis yet. Import-
antly, current therapeutic strategies for sarcoidosis (such
as corticosteroids, methotrexate/azathioprine/mycophe-
nolate mofetil, and anti-TNFα treatment) were not de-
signed according to any of the recently identified genetic
and environmental risk factors.
Although the precise cause of inflammation in sarcoid-
osis remains an enigma, it is well-established that CD4+
T helper cells and macrophages play critical roles during
granuloma formation [19]. In addition to CD4+ T cells,
CD8+ T cells have also been found in granulomas and
BAF [20,21], while its role in the pathogenesis of sar-
coidosis is unclear. Locally and systemically activated
macrophages release cytokines and chemokines such as
IL-1β, IL-6, IL-23, IL-12, IL-18, and CCL20, leading to
the recruitment of IL-17 producing T helper 17 (Th17)
cells to granulomas [22-25]. IL-17 is physiologically crit-
ical during host defense against bacterial, mycobacterial,
and fungal infections [26]. However, IL-17 producing
Th17 cells have been the leading cause of pathological
inflammation in many diseases such as multiple sclerosis
and rheumatoid arthritis [27]. Recent studies have found
a predominant increase of IL-17A+CD4+ memory T cells
in the peripheral blood and bronchoalveolar lavages of
pulmonary sarcoidosis patients [22,24], strongly suggest-
ing (Th17) cells may play an important role in the
pathogenesis of sarcoidosis.
Our previous study has suggested an elevated IL-17RC
expression on several types of cells in the peripheral
blood and retinal tissues from patients with Age-related
Macular Degeneration [28]. Therefore, in this study, we
explored whether the expression of IL-17RC was chan-
ged in ocular sarcoidosis patients.Methods
Patients
All protocols were approved by institutional review
boards, and written informed consents were provided by
the patients to the National Institutes of Health. The pa-
tient information including disease activity and medica-
tions was listed in Table 1. All patients present ocular
manifestations. 10 of these 13 patients were biopsy
proven; 3 of them were with active disease when blood
samples were drawn; 4 of these 13 patients had sarcoid
manifestations involving in organs other than the eye. The
majority of these patients were on medications (listed in
Table 1).Detection of cell surface molecules by flow cytometry
Whole blood, collected in sodium-heparin vacutainers
(BD, CA), from patients or healthy volunteers was first
subjected to red blood cell lysis using ACK lysis buffer
(Quality Biological Inc, MD). Cells were then incubated in
sterile PBS supplemented with 2% FCS and fluorochrome-
conjugated antibodies against CD3, CD4, CD8, CD14,
CD19, CD56 (all from BD, CA) and IL-17RC (FAB22691A)
and mouse-IgG2B isotype control (both from R&D, MN),
for 30 minutes at room temperature in the dark. Cells were
washed three times and analysed on a MACSQuant flow
cytometer (Miltenyi Biotec, Germany). All flow cytometry
data were analysed using FlowJo 7.6 (Treestar, OR).
ELISA
Sera from sarcoidosis patients and healthy controls were
centrifuged at 1400 rpm for 15 min after 30 min of clot-
ting and were stored at −80°C, followed by detection of
IL-17A using the Human IL-17 Quantikine ELISA Kit
(R&D Systems, Minneapolis, MN) according to the man-
ufacture’s protocol.
Cell culture
CD8+ T cells were first isolated from peripheral blood of
healthy controls or Sarcoidosis patients using EasySep
Human CD8 Positive Selection Kit (StemCell Technolo-
gies, Canada). The cells were then cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 1X penicillin-streptomycin
Figure 1 Frequency of IL-17RC+ cells among peripheral blood
cells. The frequency of IL-17RC+CD3+CD4+ T cells, IL-17RC+CD14+
monocytes, IL-17RC+CD19+ B cells, and IL-17RC+CD56+ NK cells among
each cell types in the peripheral blood from 16 healthy controls
(Healthy) and 13 patients with ocular sarcoidosis (Sa) was shown.
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bound anti-CD3 (5 ng/ml) and anti-CD28 (2 ng/ml) anti-
bodies (both from eBioscience, CA), with or without
IL-17A (100 ng/ml) for 3 days.
Immunohistochemistry
Immunohistochemistry was performed as previously de-
scribed [28]. Briefly, the citrate retrieval and avidin-biotin-
complex immunoperoxidase technique was utilized on the
unstained, de-paraffinized slides of two eyes from two pa-
tients with clinically active or quiet sarcoidosis. The pri-
mary antibody was rabbit anti-human IL-17RC polyclonal
antibody (sc-99937) (Santa Cruz Biotechnology, CA) or
control rabbit IgG. The secondary antibody was biotin-
conjugated goat anti-rabbit IgG (Vector Laboratories,
Burlingame, CA). The substrate was avidin-biotin-
peroxidase complex (Vector Laboratories, Burlingame,
CA), and the chromogen was diaminobenzidine and
nickel sulfate. The positive reaction will result in the pro-
duction of a brown-blackish color.
Microdissection and RT-PCR
Microdissection of retinal tissues and RT-PCR assays for
IL17RC expression were conducted as previously de-
scribed [27]. Briefly, retinal tissues with either granuloma-
tous inflammation (inflammatory) or non-inflammatory
(normal) areas were microdissected. Total RNA was iso-
lated using the Paradise RNA isolation kit (Applied Bio-
systems, CA). SYBR Green (Qiagen) primers were used
for human IL17RC detection. All data were normalized to
the beta-actin mRNA level. Expression fold-change was
calculated by 2-ΔΔCT.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5.0 software (GraphPad, CA). The Mann–Whitney test
was used to compare differences between two groups
and the significance level was set at P < 0.05.
Results
Elevated expression of IL-17RC on CD8+ T cells in peripheral
blood of patients with ocular sarcoidosis
Our previous study identified a hypomethylated IL17RC
promoter and elevated expression of IL17RC on CD14+
monocytes in the peripheral blood of patients with age-
related macular degeneration [28]. Sarcoidosis has been
suggested as a Th17 disease [19] and IL17RC is critical
in mediating IL-17 induced tissue damage [29]. There-
fore, we first tested whether the expression of IL-17RC
was increased on PBMCs from patients with ocular sar-
coidosis. FACS analysis of cell surface IL-17RC expres-
sion and markers identifying several major types of cells
among PBMCs were performed. Intriguingly, the fre-
quency of IL-17RC+ cells among CD3+CD4+ helper Tcells, CD14+ monocytes, CD19+ B cells, and CD56+ NK
cells was similar between healthy controls and ocular
sarcoidosis patients (Figure 1). Importantly, we found
that IL-17RC expression was significantly elevated only
in CD8+ T cells in sarcoidosis patients as compared to
healthy controls (Figure 2), suggesting a potential role
the IL-17RC+CD8+ T cells may play in the pathogenesis
of ocular sarcoidosis.
Induction of IL-17RC expression by IL-17A in activated
CD8+ T cells
Very few cells were found to express cell-surface IL-
17RC in the peripheral blood of healthy volunteers. It is
unclear how IL-17RC was induced in CD8+ T cells in
sarcoidosis patients. Our previous study suggested that
IL-17, the ligand of IL-17RC, can induce IL-17RC ex-
pression in human monocyte and retinal pigment epi-
thelium (RPE) [28]. Importantly, we found significantly
elevated levels of IL-17 in the serum of patients with
ocular sarcoidosis (Figure 3A). Therefore, we next exam-
ined whether IL-17 can induce the expression of IL-
17RC on CD8+ T cells. CD8+ T cells were isolated from
peripheral blood of healthy controls or Sarcoidosis pa-
tients and stimulated by plate-bound anti-CD3 and anti-
CD28 antibodies with or without IL-17 for 3 days. As
shown in Figure 3B, IL-17 significantly increased the ex-
pression of IL-17RC in the culture of peripheral CD8+ T
cells from healthy controls. Consistent with the above
results that an elevated expression of IL-17RC was found
on CD8+ T cells in peripheral blood from patients with
ocular sarcoidosis (Figure 2), more IL-17RC+ cells were
found in the cultures of CD8+ T cells, stimulated by
plate-bound anti-CD3 and anti-CD28 antibodies for
3 days, from sarcoidosis patients than in the culture of
CD8+ T cells from healthy controls (Figure 3B). However,
Figure 2 Frequency of IL-17RC+CD8+ T cells. The frequency of
IL-17RC+CD3+CD8+ T cells among peripheral CD8+ T cells from 18
healthy controls and 13 patients with ocular sarcoidosis.
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sponse to IL-17 treatment on CD8+ T cells from sarcoid-
osis patients (Figure 3B).
Elevated expression of IL-17RC in the eyes from patients
with clinically active ocular sarcoidosis
Previous studies have suggested that IL-17RC+ cells may
be able to migrate to the eye [28], we therefore tested
whether IL-17RC+ cells could be found in the retinal tis-
sues of patients with either active or quiet ocular sarcoid-
osis. As shown in Figure 4A-D, immunohistochemistry
assays demonstrated that IL-17RC expression in the ret-
inal tissues of patients with clinically active ocular sarcoid-
osis (Figure 4A and B) was higher than its expression in
the eye from patients with quiet disease clinically but
small focal inflammation histopathologically (Figure 4C
and D). In addition, in the eye with clinically active sar-
coidosis, IL17RC RNA expression averaged at 108.1 fold
higher in the retinal inflammatory lesion but only 14.2 foldFigure 3 Induction of IL-17RC on CD8+ T cells. (A) Serum levels of IL-17
frequency of IL-17RC+ in cultured CD8+ T cells treated with (IL-17) or withouthigher in the normal retina compared to the normaliza-
tion with beta-actin mRNA level. However, IL17RC ex-
pression was below the detectable level in both the
inflammatory and normal retina of the eye with clinically
quiet disease (Figure 4E). Taken together, these data sug-
gest that the expression of IL-17RC may correlate with
the clinical disease severity.
Discussion
Both Th1 and Th17 cells have been found to be crucial
in leading to the formation of granulomas, the clinical
hallmark of sarcoidosis [22]. An elevated level of IL-17
has been found in granulomas in the lung, BAF, as well
as circulating CD4+ T cells in patients with pulmonary
sarcoidosis [24,30]. In our study, we also found a signifi-
cant increase in the serum level of IL-17 in patients with
ocular sarcoidosis as compared to healthy controls.
Therefore, IL-17 mediated chronic inflammation may be
a leading cause of tissue pathology in sarcoidosis.
Our previous study suggests that IL-17 is able to up-
regulate the expression of its own receptor, IL-17RC, on
multiple cell types including CD14+ monocytes and ret-
inal pigment epithelium to amplify its biological effects
[28]. In our current study, we also found that IL-17 can
induce the expression of IL-17RC on peripheral CD8+ T
cells. Therefore, the elevated expression of IL-17RC in
the peripheral blood of patients with ocular sarcoidosis
may be due to the effect of increased serum level of IL-
17 in these patients. However, as shown in Figure 1, the
frequency of IL-17RC+ monocytes and NK cells was also
slightly increased, without a statistical significance prob-
ably due to the small sample size. Therefore, elevation in
the expression of IL-17RC may not be CD8+ T cell spe-
cific. It could be a common response of multiple cell
types in the peripheral blood due to the elevated level of
IL-17. Importantly, we found sustained expression of IL-
17RC protein and transcripts in the retinal tissue with
granulomatous inflammation of clinically active but not
quiet sarcoidosis patients. These results suggested thatin 18 healthy controls and 13 patients with ocular sarcoidosis. (B) The
(Con) IL-17 from 4 healthy controls and 4 sarcoidosis patients. *P < 0.05.
Figure 4 Expression of IL-17RC in the retinal tissue of patients with active or quiet ocular sarcoidosis. HE staining (A) and immunohistochemistry
staining of IL-17RC protein in the retinal tissue of an active sarcoidosis patient (B) as well as HE staining (C) and Immunohistochemistry staining of IL-
17RC protein in the retinal tissue of a quiet sarcoidosis patient (D) were shown. The expression of IL17RC in the microdissected normal or lesion retinal
tissues from patients with quiet or active ocular sarcoidosis (E) were shown. Circle, granuloma; Red arrow, IL-17RC+ cells.
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facilitate the formation of granulomas.
CD8+ T cells, in addition to CD4+ T cells, have also
been found in granulomas [21]. We have also reported
that 10% of the lymphocytic infiltration was CD8+ T cells
but these cells were rarely found within granulomas in
an eye with clinically active sarcoidosis [31]. Candia
et al. [32] as well as Zhou et al. [33] have also suggested
a crucial role CD8+ T cells play in the pathogenesis of
sarcoidosis. In this study, we found that the frequency of
IL-17RC+CD8+ cells was increased in ocular sarcoidosis
patients, which strongly suggests involvement of inflam-
matory CD8+ T cells in sarcoidosis. Many infectious
pathogens have been found in granulomas in sarcoidosispatients. It would be interesting to investigate whether
evidence of viral infection can be identified in or around
granulomas given the potential involvement of CD8+
T cells.
A low frequency of IL-17RC+ cells in the whole blood
was found on CD8+ T cells, not only in healthy controls
but also in patients with ocular sarcoidosis. However, a
significantly more IL-17RC+ cells can be found in the
cultures of CD8+ T cells stimulated by anti-CD3/anti-
CD28 antibodies as compared to the unstimulated whole
blood test, suggesting that during active inflammation,
IL-17RC+CD8+ T cells might be activated by local anti-
gen in the eye, which might contribute to the formation
of granulomas in sarcoidosis patients.
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Our results demonstrated an elevated expression of IL-
17RC on CD8+ T cells in patients with sarcoidosis, sup-
porting a potential role of these T cells played in the
pathogenesis of ocular sarcoidosis.
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